Bond JC, Abrams J, Wesselink AK, White KO, Rothman KJ, Wise LA. Predictors of non-response to a sexual health survey in a North American preconception cohort study. J Sex Med. 2022 Nov;19(11):1707-15. doi: 10.1016/j.jsxm.2022.08.199
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Johannes C, Odom D, Bennett L, Foley D. The impact of menopause status on formal vs. informal care-seeking behavior in women with decreased sexual desire with associated distress. J Sex Med. 2010 May 1;7(Suppl. 3):123.
Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009 Jun 1;6(6):1549-60.
Britt D, Kubin M, Keininger D, Trudeau E, Sagnier P, Beneke M. Development and validation of the treatment satisfaction scale (TSS) for erectile dysfunction. J Sex Med. 2003 Oct;25(Suppl 5):S180.